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Editorial on the Research Topic
Innovative Radiopharmaceuticals in Oncology and Neurology
Personalized medicine is presented as the future of patient care. Nuclear Medicine will play a major 
role in the selection of patients for targeted therapies and in early therapy assessment with the 
investigation of phenotypes and functions using sensitive and specific SPECT and PET imaging 
techniques and theranostic approaches. Nuclear Medicine is already a key in the development of 
new therapies and targeted radionuclide therapy provides efficacious treatment modalities against 
cancer. An incredible amount of innovation is related to the use of a variety of radionuclides, new or 
improved multimodality imaging devices, and numbers of recently marketed radiopharmaceuticals 
in all medical domains and particularly cardiology, neurology, and oncology.
In this context, a network of laboratories and Nuclear Medicine departments, the IRON 
Laboratory of Excellence (Labex), has been set as part of the French “Investissements d’Avenir” 
program to help translating innovative radiopharmaceuticals into clinical testing by a multidisci-
plinary approach from the production of radionuclides using cyclotrons, to basic studies of targets 
and ligands, clinical trials, and assessment of the societal impacts of innovation in medicine in 
neurology and oncology. To foster communication between scientists, inside the Labex and with 
the international community, a series of highly specialized international “Nuclear Technologies for 
Health Symposia” has been organized annually, with the most recent edition, the third, held in 
Nantes, France, on March 10–11, 2015.
Plenary lectures given by distinguished speakers (Hank Kung, Philadelphia, PA, USA, Tom Bäck, 
Gothenburg, Sweden, Otto Boerman, Nijmegen, The Netherlands, Franck Bruchertseifer, Karlsruhe, 
Germany, and Claire Tabouret-Viaud, Geneva, Switzerland) addressed the state of the arts and new 
developments in the use of radioactivity and radiopharmaceuticals for multimodality imaging and 
therapy. The latest achievements in clinical nuclear medicine, science, and technology were discussed 
during interactive oral and poster sessions.
Selected talks were organized in four sessions: innovative tracers in neurology: from bench to 
bedside, multimodality imaging, theranostic in nuclear medicine, and targeted radionuclide therapy.
After the meeting, 12 papers were published in the Nuclear Medicine topic open by Frontiers in 
Medicine. These papers are representative of current research and development in Nuclear Medicine.
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In a review article, Chatal et al. discussed the interest of 82Rb 
PET for heart diseases, especially in obese patients and in women 
with large breasts. A great advantage of 82Rb PET is its capac-
ity to accurately measure myocardial blood flow and coronary 
reserve. 82Rb has a very short half-life (75  sec) and is obtained 
from an 82Sr/82Rb generator. A major limitation for this technol-
ogy is the low worldwide production of 82Sr, but the situation is 
improving with new production facilities, including Arronax, 
becoming active, increased production yields, and approval of 
new  generator/infuser systems.
Another radionuclide that attracts interest is 64Cu, a PET 
emitter with a longer half-life (12.7 h). 64Cu may be used to label 
peptides and antibodies. Another potential application is the 
mapping of tumor hypoxia using 64Cu-ATSM, as discussed by 
Colombié et al. Hypoxic cells are more resistant to chemotherapy 
and to external beam radiation therapy. Delivering increased 
radiation doses to tumor hypoxic areas delineated by PET imag-
ing could improve response. However, there is some controversy 
about the actual cause of increased 64Cu-ATSM in tumor tissues. 
Corroyer-Dulmont et  al. made a rather comprehensive review 
of the various methods that may be used to assess oxygenation/
hypoxia, focusing on glioblastoma: other PET tracers such as [18F]
Fluoromisonidazole ([18F]FMISO) as well as many other imaging 
approaches, including MRI. They conclude that PET imaging may 
be the most relevant tool to characterize hypoxia in glioblastoma.
PET imaging is also useful in neurodegenerative diseases with 
the new tracers of amyloid plaques and in stroke with tracers of 
neuroinflammation. The objective of the paper by Sérrière et al. 
was to evaluate the effects of a new agonist of α7R on striatal 
dopaminergic neurodegeneration and neuroinflammation in a 
rat model of Parkinson Disease by PET imaging with [18F]LBT-
999 to quantify the striatal dopamine transporter. Thanks to the 
use of preclinical PET imaging, they could conclude that an α7R 
agonist may be beneficial for the treatment of Parkinson Disease.
In cancer diseases, [18F]FDG and [18F]fluorocholine are the 
most commonly used tracers in clinical practice. In a retrospec-
tive study, Rusu et  al. evaluated the contribution of [18F]FDG 
PET to the clinical management and survival outcome of patients 
suspected of recurrent ovarian carcinoma. They showed that early 
diagnosis of recurrent ovarian cancer by PET had a significant 
impact on treatment planning and predicted patient outcome. In 
prostate cancer, Mathieu et al. reported interest of dynamic PET/
CT image acquisition with [18F]fluorocholine to define pelvic 
lymph node or prostate pathological status.
Nuclear Medicine is also therapy. This has been known 
for many years, with the use of 131I in the treatment of thyroid 
cancer. Tracking other cancers remains a challenge, but progress 
is made. New radioactive therapeutic agents are designed to 
improve response and survival, while minimizing side-effects. 
Locoregional injection of radioactive microparticles is in use 
in hepatic cancers. Encapsulation of radionuclides in nanopar-
ticles that could be injected systemically has been proposed as 
a way to increase the radioactive load and reduce exposure of 
normal tissues. Lepareur and coworkers described non-toxic 
nanoparticles, able to release their load in a controlled way. They 
prepared biodegradable and biocompatible pegylated nanopar-
ticles loaded with a lipophilic 99mTc-labeled tracer that may be 
labeled by 188Re for therapy (Lepareur et  al.). Targeting similar 
nanoparticles is also explored by Rauscher et  al., who develop 
pegylated liposomes labeled with 111In and 125/131I for pretargeted 
radioimmunotherapy, using a bispecific monoclonal antibody 
recognizing a tumor antigen and a small molecular weight tag 
attached to the surface of the liposomes. Immunospecific tumor 
targeting was demonstrated in vitro and in vivo in a mouse model.
With small radiolabeled molecules, clinical proofs of con-
cept have been obtained for a variety of pretargeting methods 
in single photon imaging, PET imaging, and therapy. The key 
is the bispecific pretargeting agent and the optimization of the 
pretargeting protocol. Bodet-Milin et  al. studied a new class 
of bispecific antibodies in a phase I radioimmunotherapy trial 
(http://ClinicalTrials.gov NCT01221675) to optimize pretarget-
ing parameters. The best dosing parameters were a short pretar-
geting delay (24 h) and a high bispecific molar dose.
A promising avenue for cancer therapy is the use of alpha-
particle emitters. Alpha particles have very short tracks (usually 
less than 100 µm) and a very high cytotoxic potential even against 
radioresistant tumor cells in hypoxic area. 223Ra, a bone targeting 
agent, has been recently approved for symptomatic metastatic 
prostate cancer therapy. Antibodies may be used to target other 
alpha-emitting radionuclides. Here, 213Bi has been targeted to 
multiple myeloma, in a syngeneic mouse model, by means of 
an anti-CD138 antibody. Fichou et al. demonstrated that 213Bi is 
much more effective than 177Lu. The higher efficacy in such dis-
seminated diseases has been presented as the major interest and 
the best rationale for the use of alpha emitters in therapy, but this 
is one of the first direct comparisons. In the same model, Gorin 
et  al. showed that autophagy is a prominent cell death mecha-
nism with 213Bi. Derrien et al. confirmed the efficacy of locally 
delivered antibodies labeled with 213Bi in an ovarian cancer model 
and proposed combination with hyperthermic intraperitoneal 
chemotherapy in an attempt to treat advanced disease.
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